|
業務類別
|
Biotechnology |
|
業務概覽
|
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291. |
| 公司地址
| 11711 N. Meridian Street, Suite 300, Carmel, IN, USA, 46032 |
| 電話號碼
| +1 317 659-0200 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.mbxbio.com |
| 員工數量
| 63 |
| Mr. Stephen L. Hoerter |
Executive Chairman of the Board, President and Chief Executive Officer |
-- |
13/07/2026 |
| Mr. John W. Smither |
Chief Financial Officer |
-- |
13/07/2026 |
| Dr. Salomon Azoulay, M.D. |
Chief Medical Officer |
美元 488.50K |
22/04/2026 |
|
|
| Mr. Edward T. Mathers |
Independent Director |
22/04/2026 |
| Mr. Patrick J. Heron |
Lead Independent Director |
22/04/2026 |
| Dr. Ora H. Pescovitz, M.D. |
Independent Director |
22/04/2026 |
| Mr. Stephen L. Hoerter |
Executive Chairman of the Board, President and Chief Executive Officer |
13/07/2026 |
| Ms. Laurie D. Stelzer, M.B.A. |
Independent Director |
22/01/2026 |
| Dr. Tiba Aynechi, PhD |
Independent Director |
22/04/2026 |
| Dr. Steven Ryder, M.D. |
Independent Director |
22/04/2026 |
|
|
|
|
